Business Wire

TX-SONAR

1.5.2024 15:01:34 CEST | Business Wire | Press release

Share
Lynne Doherty Joins Sonar as President of Field Operations

Sonar announced today that Lynne Doherty will join the organization as President of Field Operations. In her new role, Lynne will be responsible for driving revenue, and ensuring that Sonar's customers are successful in their pursuit of Clean Code. The leading provider of Clean Code solutions, Sonar accelerates mission-critical software development, reduces technical debt, and improves code quality and code security. Lynne will lead the company’s demand generation, global sales, solutions engineering, customer success, and customer support teams globally.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240501287633/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Lynne Doherty joins Sonar as President of Field Operations to accelerate revenue growth and global expansion. (Photo: Business Wire)

“Lynne has an outstanding track record of leading high-performing go-to-market organizations and driving positive business outcomes. We are excited that she is joining Sonar and believe she’s the ideal leader to help us in our next phase of growth,” said Tariq Shaukat, co-CEO of Sonar. “Having started her career as a Software Developer, she has a strong understanding of the value Sonar creates and a proven track record of working with customers to achieve that value.”

Lynne brings more than 20 years of sales leadership experience to Sonar, most recently as President, of Worldwide Field Operations at Sumo Logic, where she was focused on evolving the GTM organization for operational scale and speed. This included driving customer expansion and growing new logos, shifting the segmentation model, and starting a partner-first motion. Before that, she held various leadership roles at McAfee, where she drove over a billion dollars of revenue annually. In her time at McAfee, she led the team through several business evolutions, supported McAfee’s initial public offering, and multiple acquisitions.

“Sonar is a crucial tool for software developers and engineering teams that is especially necessary for AI-assisted code. With its Clean Code methodology, Sonar addresses a significant gap in the software development lifecycle, enhancing code quality and security hand-in-hand,” said Doherty. “Joining the Sonar team feels personal for me, in a sense, as I’m getting back to my roots as a developer, where I started my career. I’m thrilled to join the Sonar team and look forward to working alongside Tariq, Olivier, and the rest of the organization to deliver Clean Code.”

Before joining McAfee, Lynne held various sales and marketing leadership roles at Cisco, where she oversaw a team of more than 2,000 employees, and drove billions in revenue annually. While at Cisco, she also played a key role in the success of acquisitions of Duo Security, Umbrella, and Cloudlock. Lynne is an independent Director on the boards of CloudBees and the American Red Cross. She holds a B.S. in Mathematics and Computer Science from Temple University.

Over the last 15 years, Sonar has analyzed more than half-a-trillion lines of code across all industries and company sizes, resulting in a deep understanding of how code is written and managed. With that knowledge, Sonar has redefined what it means to write Clean Code in today’s software development life cycle, helping organizations accelerate mission-critical software development, manage proliferating risks, and build fast and reliable applications.

Sonar is currently hiring across a number of departments. You can learn more about joining the Sonar team here.

About Sonar

Sonar is a leading developer of open source solutions to help developers write Clean Code. Sonar’s solutions — SonarQube, SonarCloud, and SonarLint — support over 30 programming languages, frameworks, and infrastructure technologies. Trusted by more than 400,000 organizations globally to clean more than half a trillion lines of code, Sonar is integral to delivering higher quality, better-performing software.

To learn more about Sonar, please visit: https://www.sonarsource.com/products/all/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240501287633/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye